After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA —were still alive without a lymphoma relapse, according to long-term follow-up data published in New England Journal of Medicine by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

In the analysis of 38 patients from a Phase II clinical trial (including 24 patients with large B-cell lymphoma and 14 with follicular lymphoma) conducted at Penn Medicine’s Abramson Cancer Center, no patients experienced a relapse after 5.4 years, and most relapses occurred within the first year after CAR T-cell infusion, supporting the hypothesis that patients who experience a long-term response to CAR T-cell therapy may be cured.

“As oncologists, we use the word ‘cure’ with great care, but I am increasingly confident that CAR T-cell therapy has the potential to cure a meaningful number of patients with B-cell lymphomas,” said senior author Stephen J. Schuster, MD, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research and director of Penn’s Lymphoma Program.